Liver cancer is sometimes referred to as hepatic cancer or primary hepatic malignancy. It is the sixth most common type of cancer worldwide. Moreover, it is the fourth main cause of cancer-related deaths. 75% of primary liver malignancies are hepatocellular carcinomas (HCCs), making them the most prevalent kind. Liver cancer manifests as fever, weight loss, jaundice, and abdominal pain. Aflatoxin exposure, cirrhosis from alcohol, and hepatitis B and C infections are risk factors. Among the available treatment options include liver transplantation, radiation therapy, targeted therapy, and surgery. Moreover, the rising prevalence of the condition is anticipated to positively impact the pipeline landscape for liver cancer drugs.
Report Coverage
The Liver Cancer Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into liver cancer therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for liver cancer. The liver cancer report assessment includes the analysis of over 25 pipeline drugs and 10+ companies. The liver cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with liver cancer treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to liver cancer.
Liver Cancer Drug Pipeline Outlook
Hepatocellular carcinoma (HCC) is the most common type of liver cancer and has a complicated and multiple pathogenesis. One important stage in the viral carcinogenesis of HCC4 is cirrhosis. Chronic alcohol use, aflatoxin-B1-contaminated diet, and persistent hepatitis B (HBV) and C (HCV) viral infections have all been connected to the development of HCC. HBV can affect the development of liver cancer by increasing the expression of activating transcription factor 7 (ATF7), which promotes cell proliferation and inhibits apoptosis. Additionally, viral proteins can control cellular signaling pathways. HBV-induced hepatocarcinogenesis is caused by a combination of host-viral interactions, prolonged cycles of necrosis, inflammation, and regeneration, viral integration into the host genome, and the specific activation of oncogenic pathways by different viral proteins.
Small molecules are the most popular kind for treating liver cancer because of their capacity to effectively enter cells and target important oncogenic pathways. Small molecule tyrosine kinase inhibitors, such sorafenib and lenvatinib, are used to treat hepatocellular carcinoma (HCC) and decrease tumor growth and angiogenesis. Small molecules have superior oral bioavailability and systemic dispersion compared to oligonucleotides and peptides, which makes them more useful for treating liver cancer. Nevertheless, oligonucleotide and peptide-based treatments are being investigated for potential future developments. Further, the rising focus on the development of liver cancer emerging drugs and the advances in the understanding of the molecular pathogenesis of the disease are expected to support the pipeline expansion in the coming years.
Liver Cancer Epidemiology
Globally, liver cancer ranks as the sixth most common type of cancer. There were 866,136 new cases in 2022. Asia is home to almost 75% of liver cancer cases, with China bearing more than 50% of the global burden. The country with the greatest incidence rate is Mongolia. Males typically have two to three times the incidence and fatality rates of females. The fourth most frequent cause of cancer-related fatalities worldwide is liver cancer. According to the American Cancer Society, 42,240 new cases are expected to be detected in the United States in 2025.
Liver Cancer – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of liver cancer drug candidates based on several segmentations including:
By Phase
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook